Physician profile
Abdur Rauf
NPI 1548268527
$5,504.63
in general payments reported to CMS, 2019-2025
26 companies · $814 in 2025
The $814 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $314 · 2021: $324 · 2022: $682 · 2023: $975 · 2024: $1,835 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,609 · Education: $14.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.70 |
| Education | $14.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $951.52 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $618.37 | 2019-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $487.71 | 2022-2024 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $349.86 | 2022-2025 | Epclusa |
| Phathom Pharmaceuticals, INC. | $292.77 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $187.25 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $151.38 | 2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Iqirvo |
| Boston Scientific Corporation | $141.05 | 2023 | Resolution 360 Clip, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $113.60 | 2019-2024 | Dificid |
| Allergan, INC. | $109.00 | 2019 | |
| Celgene Corporation | $90.33 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $88.33 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $66.26 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $55.54 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $44.48 | 2019 | |
| Braintree Laboratories, INC. | $39.47 | 2019-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $36.02 | 2020-2021 | |
| Celltrion USA INC. | $32.29 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $30.31 | 2019-2020 | |
| Shionogi INC | $26.04 | 2019 | |
| Amgen INC. | $13.46 | 2025 | Uplizna |
| Pfizer INC. | $11.40 | 2021 | |
| Alnylam Pharmaceuticals INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdur Rauf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.